NO20030495D0 - Peptider som presenteres av celler - Google Patents

Peptider som presenteres av celler

Info

Publication number
NO20030495D0
NO20030495D0 NO20030495A NO20030495A NO20030495D0 NO 20030495 D0 NO20030495 D0 NO 20030495D0 NO 20030495 A NO20030495 A NO 20030495A NO 20030495 A NO20030495 A NO 20030495A NO 20030495 D0 NO20030495 D0 NO 20030495D0
Authority
NO
Norway
Prior art keywords
peptides
cells
determination
peptides presented
relates
Prior art date
Application number
NO20030495A
Other languages
English (en)
Other versions
NO20030495L (no
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20030495D0 publication Critical patent/NO20030495D0/no
Publication of NO20030495L publication Critical patent/NO20030495L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20030495A 2000-08-03 2003-01-31 Peptider som presenteres av celler NO20030495L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (2)

Publication Number Publication Date
NO20030495D0 true NO20030495D0 (no) 2003-01-31
NO20030495L NO20030495L (no) 2003-01-31

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030495A NO20030495L (no) 2000-08-03 2003-01-31 Peptider som presenteres av celler

Country Status (20)

Country Link
US (1) US20030171290A1 (no)
EP (1) EP1305343B1 (no)
JP (1) JP2004506202A (no)
KR (1) KR20030037272A (no)
CN (1) CN1511164A (no)
AT (1) ATE306498T1 (no)
AU (1) AU2001283958A1 (no)
BR (1) BR0112925A (no)
CA (1) CA2417767A1 (no)
CZ (1) CZ2003464A3 (no)
DE (1) DE60114018T2 (no)
GB (1) GB0018901D0 (no)
HU (1) HUP0301581A2 (no)
MX (1) MXPA03000901A (no)
NO (1) NO20030495L (no)
PL (1) PL358874A1 (no)
RU (1) RU2003105806A (no)
SK (1) SK1982003A3 (no)
WO (1) WO2002012899A2 (no)
ZA (1) ZA200301637B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023202A2 (en) * 2000-09-18 2002-03-21 Genzyme Corporation Method to identify antibody targets based on mass spectrometry (maldi-tof)
JP4188229B2 (ja) * 2001-06-19 2008-11-26 サントリー株式会社 細胞内に存在するタンパク質又は当該タンパク質と相互作用する物質を分析する方法
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
SI1673398T1 (sl) 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) * 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
KR20120104558A (ko) 2009-11-05 2012-09-21 세파론 오스트레일리아 피티와이 엘티디 돌연변이형 ｋｒａｓ 또는 ｂｒａｆ 유전자를 포함하는 암을 치료하는 방법
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
MX2015015638A (es) * 2013-05-13 2016-10-28 Cellectis Metodos para diseñar celulas t altamente activas para inmunoterapia.
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
EP3356522A4 (en) * 2016-09-30 2019-03-27 Cellex Life Sciences, Incorporated PROTEIN-PROTECTED EXOSOME-CONTAINING COMPOSITIONS AND METHODS FOR PREPARING AND ADMINISTERING SAME
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
WO2000064466A1 (en) * 1999-04-28 2000-11-02 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
DE60114018T2 (de) 2006-06-29
HUP0301581A2 (hu) 2003-08-28
ZA200301637B (en) 2004-02-03
CN1511164A (zh) 2004-07-07
EP1305343B1 (en) 2005-10-12
JP2004506202A (ja) 2004-02-26
US20030171290A1 (en) 2003-09-11
BR0112925A (pt) 2003-08-26
WO2002012899A2 (en) 2002-02-14
NO20030495L (no) 2003-01-31
SK1982003A3 (en) 2003-08-05
AU2001283958A1 (en) 2002-02-18
RU2003105806A (ru) 2004-07-20
KR20030037272A (ko) 2003-05-12
EP1305343A2 (en) 2003-05-02
ATE306498T1 (de) 2005-10-15
MXPA03000901A (es) 2003-06-24
PL358874A1 (en) 2004-08-23
DE60114018D1 (de) 2006-02-23
GB0018901D0 (en) 2000-09-20
CZ2003464A3 (cs) 2003-06-18
WO2002012899A3 (en) 2002-11-07
CA2417767A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
NO20030495L (no) Peptider som presenteres av celler
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
ATE380822T1 (de) Funf-helix protein
AR038568A1 (es) Anticuerpos anti-a beta y su uso
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2002002783A3 (en) Expression vectors
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
WO2003106657A3 (en) NUCLEOTIDE SEQUENCES AND AMINO ACID SEQUENCES WISE / SOST
WO2004007547A3 (en) Truncated tau proteins
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60313659D1 (de) Borrelidin-derivate und ihre medizinische anwendung
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU8405798A (en) A swine hepatitis e virus and uses thereof
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2002102847A1 (fr) Nouveau ligand et son adn
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
WO2005044849A3 (en) Lp mammalian proteins; related reagents